| Identification | Back Directory | [Name]
Necrox-5 (methanesulfonate) | [CAS]
1383718-29-3 | [Synonyms]
NecroX-5
NecroX-5 mesylate
Necrox-5 (methanesulfonate)
ZWWWDIWEZYRVMB-UHFFFAOYSA-N | [Molecular Formula]
C26H35N3O6S2 | [MDL Number]
MFCD28147672 | [MOL File]
1383718-29-3.mol | [Molecular Weight]
549.7 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMF:PBS(pH 7.2)(1:6): 0.1 mg/ml; DMSO: 1 mg/ml; Ethanol: 0.25 mg/ml | [form ]
A crystalline solid | [color ]
Light brown to brown |
| Hazard Information | Back Directory | [Description]
NecroX-5 is an inhibitor of necrosis/necroptosis. NecroX-5 has been shown to scavenge mitochondrial reactive oxygen and nitrogen species, and thus preventing necrotic cell death against various kinds of oxidative stress in several tissues, including the brain. | [Uses]
NecroX-5 is a derivative of the NecroX, reduces intracellular calcium concentration, and possesses anti-inflammatory and anti-cancer activity. | [in vivo]
NecroX-5 (2.5 mg/kg, everyday other day) inhibits breast cancer cell metastasis in TUBO-P2J tumour-bearing mice[1]. | [References]
[1] Park JH, et al. NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. Int J Oncol. 2017 Jan;50(1):185-192. DOI:10.3892/ijo.2016.3789
[2] Thu VT, et al. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts. Korean J Physiol Pharmacol. 2016 May;20(3):305-14. DOI:10.4196/kjpp.2016.20.3.305 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|